Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Prothena Corporation stock

PRTA
IE00B91XRN20
A1KAVV

Price

14.23
Today +/-
-0.45
Today %
-3.25 %

Prothena Corporation stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Prothena Corporation stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Prothena Corporation stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Prothena Corporation stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Prothena Corporation's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Prothena Corporation Stock Price History

DateProthena Corporation Price
1/31/202514.23 undefined
1/30/202514.70 undefined
1/29/202515.81 undefined
1/28/202515.96 undefined
1/27/202516.04 undefined
1/24/202515.62 undefined
1/23/202515.48 undefined
1/22/202514.43 undefined
1/21/202514.11 undefined
1/17/202513.77 undefined
1/16/202513.18 undefined
1/15/202513.27 undefined
1/14/202512.67 undefined
1/13/202513.13 undefined
1/10/202513.05 undefined
1/8/202514.16 undefined
1/7/202514.15 undefined
1/6/202513.15 undefined

Prothena Corporation Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Prothena Corporation, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Prothena Corporation from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Prothena Corporation’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Prothena Corporation. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Prothena Corporation’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Prothena Corporation’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Prothena Corporation’s growth potential.

Prothena Corporation Revenue, EBIT and net profit per share

DateProthena Corporation RevenueProthena Corporation EBITProthena Corporation Net Income
2030e1.63 B undefined0 undefined1.07 B undefined
2029e1.01 B undefined471.57 M undefined476.23 M undefined
2028e610.09 M undefined111.37 M undefined135.71 M undefined
2027e374.32 M undefined-73.67 M undefined-49.4 M undefined
2026e146.59 M undefined-245.39 M undefined-183.05 M undefined
2025e65.21 M undefined-264.94 M undefined-225.96 M undefined
2024e143.35 M undefined-158.01 M undefined-122.78 M undefined
202391.37 M undefined-191.04 M undefined-147.03 M undefined
202253.9 M undefined-131.6 M undefined-116.9 M undefined
2021200.6 M undefined72 M undefined67 M undefined
2020900,000 undefined-112.7 M undefined-111.1 M undefined
2019800,000 undefined-85.8 M undefined-77.7 M undefined
20181 M undefined-142.8 M undefined-155.6 M undefined
201727.5 M undefined-155.3 M undefined-153.2 M undefined
20161.1 M undefined-159.5 M undefined-160.1 M undefined
20151.6 M undefined-79.9 M undefined-80.6 M undefined
201450.9 M undefined-6.6 M undefined-7.2 M undefined
2013700,000 undefined-40.4 M undefined-41 M undefined
20122.7 M undefined-41.4 M undefined-41.4 M undefined
2011500,000 undefined-29.3 M undefined-29.8 M undefined
20101.2 M undefined-12.2 M undefined-12.5 M undefined
20092.5 M undefined-1.2 M undefined-1.3 M undefined

Prothena Corporation Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
000000.05000.030000.20.050.090.140.070.150.370.611.011.63
--50.00-----98.00-2,600.00-96.30----73.5071.7057.14-54.55124.62156.1663.1064.7562.59
----------------------
0000000000000000000000
-0-0.01-0.03-0.04-0.04-0.01-0.08-0.16-0.15-0.16-0.08-0.110.07-0.12-0.15-0.12-0.23-0.18-0.050.140.481.07
-1,100.00141.6741.38--82.931,042.86100.00-4.381.31-50.3244.16-160.36-273.1326.72-17.0184.43-18.67-73.22-375.51252.59124.58
14.514.514.514.618.624.730.334.437.739.639.939.948.547.453.220000000
----------------------
Details

Keystats

ⓘ

Revenue and Growth

The Prothena Corporation Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Prothena Corporation is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
20102011201220132014201520162017201820192020202120222023
                           
00124.9176.7293.6370.6386.9417.6427.7375.7295.4579.1710.4618.83
000.20.11.80.50.20.200.10005.16
00000000000000
00000000000000
00.10.81.53.86.34.38.53.72.63.95.78.715.29
00.1125.9178.3299.2377.4391.4426.3431.4378.4299.3584.8719.1639.28
2.42.53.43.43.13.956.55552.827.120.414.1816
00000000000000
00000000000000
0100000000000000
00000000000000
0.90.900.81.9412.21514.613.713.310.430.941.1
3.33.53.44.257.968.77067.440.833.724.538.957.1
3.33.6129.3182.5304.2385.3460.1496.3498.8419.2333609.3758696.38
                           
00200200300300300400400400400500500537
000.130.210.340.490.650.850.920.940.971.181.451.54
00-0.3-41.3-48.5-129.1-289.2-442.4-598-671.9-783-716.1-833-980.03
0.1-6.400000000000561.37
00000000000000
0-0.010.130.170.290.360.370.410.320.270.180.470.621.12
0.20.401.84.74.513.113.61.51.24.13.79.325.39
1.47.71.64.45.416.625.720.99.915.720.520.928.329.08
0.20.30.11.21.91.12.32.21.90.71.28.812.62.42
00000000000000
00000000.71.600000
1.88.41.77.41222.241.137.414.917.625.833.450.256.89
000000051.549.900000
00000000000000
1.41.71.11.72.22.453.50.3111128.6123.1109.985.878.13
1.41.71.11.72.22.453.551.8160.9128.6123.1109.985.878.13
3.210.12.89.114.224.694.689.2175.8146.2148.9143.3136135.02
000.130.180.30.390.460.50.50.420.330.610.761.26
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Prothena Corporation provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Prothena Corporation's financial health and stability.

Assets

Prothena Corporation's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Prothena Corporation must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Prothena Corporation after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Prothena Corporation's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200920102011201220132014201520162017201820192020202120222023
-1-12-29-41-41-7-80-160-153-155-77-11166-116-147
000000023311100
0000000-3-2-1-1-14-11-15
016-7511118-794-43-10-18-20
03512610175055585249556889
000000000000000
000001000-111021
0-9-19-42-320-62-116-131-28-52-8092-108-133
0-20-100-1-16-3-10000-2
0-20-100-1-16-3-10000-2
000000000000000
000000000000000
00000000-2-400000
0002684117136139168440019024145
0112016884118140153165400019024145
01120142003140000000
000000000000000
0001245111677203010-53-80282132-91
-0.5-11.7-20.3-43.37-32.66-1.21-63.84-132.89-134.81-30.05-53.53-80.5692.03-109.28-136.72
000000000000000

Prothena Corporation stock margins

The Prothena Corporation margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Prothena Corporation. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Prothena Corporation.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Prothena Corporation's sales revenue. A higher gross margin percentage indicates that the Prothena Corporation retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Prothena Corporation's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Prothena Corporation's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Prothena Corporation's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Prothena Corporation. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Prothena Corporation's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Prothena Corporation Margin History

Prothena Corporation Gross marginProthena Corporation Profit marginProthena Corporation EBIT marginProthena Corporation Profit margin
2030e0 %0 %65.43 %
2029e0 %46.92 %47.39 %
2028e0 %18.25 %22.24 %
2027e0 %-19.68 %-13.2 %
2026e0 %-167.4 %-124.87 %
2025e0 %-406.27 %-346.5 %
2024e0 %-110.23 %-85.65 %
20230 %-209.08 %-160.91 %
20220 %-244.16 %-216.88 %
20210 %35.89 %33.4 %
20200 %-12,522.22 %-12,344.44 %
20190 %-10,725 %-9,712.5 %
20180 %-14,280 %-15,560 %
20170 %-564.73 %-557.09 %
20160 %-14,500 %-14,554.55 %
20150 %-4,993.75 %-5,037.5 %
20140 %-12.97 %-14.15 %
20130 %-5,771.43 %-5,857.14 %
20120 %-1,533.33 %-1,533.33 %
20110 %-5,860 %-5,960 %
20100 %-1,016.67 %-1,041.67 %
20090 %-48 %-52 %

Prothena Corporation Stock Sales Revenue, EBIT, Earnings per Share

The Prothena Corporation earnings per share therefore indicates how much revenue Prothena Corporation has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Prothena Corporation earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Prothena Corporation's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Prothena Corporation’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Prothena Corporation's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Prothena Corporation Revenue, EBIT and net profit per share

DateProthena Corporation Sales per ShareProthena Corporation EBIT per shareProthena Corporation Earnings per Share
2030e30.37 undefined0 undefined19.87 undefined
2029e18.68 undefined0 undefined8.85 undefined
2028e11.34 undefined0 undefined2.52 undefined
2027e6.96 undefined0 undefined-0.92 undefined
2026e2.72 undefined0 undefined-3.4 undefined
2025e1.21 undefined0 undefined-4.2 undefined
2024e2.66 undefined0 undefined-2.28 undefined
20231.72 undefined-3.59 undefined-2.76 undefined
20221.14 undefined-2.78 undefined-2.47 undefined
20214.14 undefined1.48 undefined1.38 undefined
20200.02 undefined-2.82 undefined-2.78 undefined
20190.02 undefined-2.15 undefined-1.95 undefined
20180.03 undefined-3.61 undefined-3.93 undefined
20170.73 undefined-4.12 undefined-4.06 undefined
20160.03 undefined-4.64 undefined-4.65 undefined
20150.05 undefined-2.64 undefined-2.66 undefined
20142.06 undefined-0.27 undefined-0.29 undefined
20130.04 undefined-2.17 undefined-2.2 undefined
20120.18 undefined-2.84 undefined-2.84 undefined
20110.03 undefined-2.02 undefined-2.06 undefined
20100.08 undefined-0.84 undefined-0.86 undefined
20090.17 undefined-0.08 undefined-0.09 undefined

Prothena Corporation business model

Prothena Corporation PLC is a biopharmaceutical company based in Dublin, Ireland, specializing in the development of therapies for protein diseases. The company was spun off from Elan Corporation's research department in 2012 and has been listed on NASDAQ since 2014. Prothena's business model is based on the discovery and development of novel therapeutic approaches for neurodegenerative diseases and cancer caused by misfolded proteins. The company leverages its expertise in protein biochemistry and physics to identify targeted drug candidates that can modulate specific protein structures and their functions. Prothena's key focus areas include researching antibodies against amyloid-beta plaques, which accumulate in the brain in Alzheimer's disease, and developing molecules that can inhibit the disease-causing protein alpha-synuclein in Parkinson's patients. Additionally, the company is working on therapies for ATTR (amyloidosis) and AL amyloidosis. A major success for Prothena was the development of NEOD001, a humanized antibody that targets the amyloid fibril protein (AL) deposited in AL amyloidosis. The drug demonstrated significant efficacy in clinical trials and improved patients' quality of life. Prothena licensed NEOD001 to Pfizer in 2017. Another important product from Prothena is PRX002, a monoclonal antibody specifically targeting the alpha-synuclein protein and inhibiting its spread in the brain. PRX002 is currently undergoing clinical trials for the treatment of Parkinson's patients and is considered a promising medication. Prothena collaborates closely with research partners and other pharmaceutical companies such as Roche/Genentech and Celgene to advance their research activities and the development of new therapeutics. The company has strong regulatory expertise and aims to obtain approvals for new therapies to provide improved quality of life for patients with rare or serious diseases. Overall, Prothena is a leading company in the field of protein biochemistry and the development of innovative therapies for protein diseases. With a strong research pipeline and a wide range of product candidates, the company has the potential to improve the lives of millions of people suffering from serious illnesses. Prothena Corporation is one of the most popular companies on Eulerpool.com.

Prothena Corporation SWOT Analysis

Strengths

Prothena Corporation is a leading biotechnology company that specializes in the discovery and development of novel therapies for neurodegenerative diseases. Their strengths include:

  • Strong scientific expertise and research capabilities in neurology and protein misfolding disorders.
  • Diverse pipeline with a focus on innovative drug candidates targeting serious neurodegenerative diseases.
  • Strategic partnerships with renowned academic institutions and pharmaceutical companies, enhancing research collaborations and potential market access.
  • Strong financial position and resources to support ongoing research and development efforts.

Weaknesses

Despite its strengths, Prothena Corporation also faces certain weaknesses that could hinder its growth and success. These weaknesses include:

  • Reliance on a limited number of drug candidates, increasing the risk of pipeline failures and reduced revenue streams.
  • Dependency on successful clinical trial outcomes, which can be unpredictable and subject to regulatory challenges.
  • Limited market presence and brand recognition compared to larger pharmaceutical companies.
  • Relatively small-scale operations and workforce, potentially limiting their ability to compete with larger industry players.

Opportunities

Prothena Corporation operates in an industry with several opportunities that can drive its growth and profitability. These opportunities include:

  • Increasing global incidence of neurodegenerative diseases, creating a growing market demand for innovative treatments.
  • Advancements in technology and understanding of disease mechanisms, providing opportunities for the development of targeted therapies.
  • Potential for strategic partnerships and collaborations to expand research capabilities and access to global markets.
  • Growing importance of personalized medicine and precision therapeutics, aligning with Prothena's focus on tailored treatments for specific patient populations.

Threats

Prothena Corporation faces various threats that could impede its progress and market position. These threats include:

  • Fierce competition from established pharmaceutical companies and emerging biotech firms in the neurodegenerative disease space.
  • Stringent regulatory requirements and potential challenges in obtaining necessary approvals for drug candidates.
  • Uncertainties related to intellectual property rights, patent expirations, and potential infringement claims.
  • Potential adverse events or safety concerns during clinical trials that could result in setbacks or reputation damage.

Prothena Corporation Revenue by Segment

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Prothena Corporation Revenue by Segment

Segmente2023202220212020
Collaboration--139.83 M USD-
Collaboration revenue91.32 M USD13.86 M USD-600,000 USD
Revenue from license and intellectual property50,000 USD40.05 M USD60.74 M USD-
License revenue---289,000 USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Prothena Corporation Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Prothena Corporation historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Prothena Corporation shares outstanding

The number of shares was Prothena Corporation in 2024 — This indicates how many shares 53.216 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Prothena Corporation earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Prothena Corporation's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Prothena Corporation’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Prothena Corporation's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Prothena Corporation.

Prothena Corporation latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-1.2 -1.1  (8.42 %)2024 Q3
6/30/2024-1.07 1.22  (213.55 %)2024 Q2
3/31/2024-1.23 -1.34  (-9.36 %)2024 Q1
12/31/2023-1.24 -1.26  (-1.53 %)2023 Q4
9/30/2023-0.33 0.38  (215.71 %)2023 Q3
6/30/2023-1.02 -1.03  (-1.4 %)2023 Q2
3/31/2023-0.96 -0.89  (7.61 %)2023 Q1
12/31/2022-0.48 0.12  (125.26 %)2022 Q4
9/30/2022-0.54 -0.97  (-79.93 %)2022 Q3
6/30/2022-0.53 -0.88  (-64.79 %)2022 Q2
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Prothena Corporation stock

Eulerpool World ESG Rating (EESG©)

58/ 100

🌱 Environment

64

👫 Social

58

🏛️ Governance

54

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees63
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Prothena Corporation shareholders

%
Name
Stocks
Change
Date
21.52812 % EcoR1 Capital, LLC11,584,28006/30/2024
14.98918 % Fidelity Management & Research Company LLC8,065,67759,2666/30/2024
7.73894 % T. Rowe Price Associates, Inc.4,164,32434,2826/30/2024
6.76348 % Wellington Management Company, LLP3,639,429-112,7186/30/2024
6.50898 % Scully (William P)3,502,4811,039,4812/5/2024
6.02146 % BlackRock Institutional Trust Company, N.A.3,240,15064,1846/30/2024
5.83806 % Fennell (Todd W.)3,141,4593,141,4592/5/2024
3.11264 % State Street Global Advisors (US)1,674,909-257,5639/30/2024
3.09678 % Palo Alto Investors LP1,666,3782,9306/30/2024
2.89909 % Armistice Capital LLC1,560,000464,0006/30/2024
1
2
3
4
5
...
10

Prothena Corporation Executives and Management Board

Dr. Gene Kinney

(54)
Prothena Corporation President, Chief Executive Officer, Director (since 2012)
Compensation 6.74 M

Dr. Wagner Zago

(50)
Prothena Corporation Chief Scientific Officer
Compensation 3.34 M

Dr. Hideki Garren

(59)
Prothena Corporation Chief Medical Officer
Compensation 2.75 M

Mr. Tran Nguyen

(49)
Prothena Corporation Chief Financial Officer, Chief Strategy Officer
Compensation 2.7 M

Mr. Brandon Smith

(48)
Prothena Corporation Chief Operating Officer
Compensation 2.7 M
1
2
3
4

Prothena Corporation Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Catalent Stock
Catalent
SupplierCustomer0,910,040,680,890,880,80
Perrigo Stock
Perrigo
SupplierCustomer0,74-0,500,400,510,71-0,28
Bristol-Myers Squibb Stock
Bristol-Myers Squibb
SupplierCustomer0,44-0,25-0,30-0,72-0,610,09
Roche Holding Stock
Roche Holding
SupplierCustomer0,070,82-0,240,09-0,230,63
Novo Nordisk B Stock
Novo Nordisk B
SupplierCustomer-0,740,64-0,15-0,10-0,430,67
1

Most common questions regarding Prothena Corporation

What values and corporate philosophy does Prothena Corporation represent?

Prothena Corporation PLC is a biotechnology company that focuses on developing transformative therapies for patients with neurodegenerative diseases. The company's values revolve around scientific innovation, integrity, collaboration, and patient-centricity. Prothena is committed to advancing the understanding of disease pathways and developing novel treatments that address unmet medical needs. With a mission to improve patient outcomes, Prothena prioritizes rigorous research, strategic partnerships, and efficient development processes. By combining cutting-edge science, a strong corporate philosophy, and a dedicated team, Prothena Corporation PLC strives to bring hope and potential breakthroughs to individuals affected by debilitating neurodegenerative conditions.

In which countries and regions is Prothena Corporation primarily present?

Prothena Corporation PLC is primarily present in the United States and Europe. As a multinational biotechnology company, Prothena focuses on the discovery, development, and commercialization of immunotherapies for the treatment of neurodegenerative diseases. With its headquarters in Ireland, Prothena maintains a strong presence in major cities across the United States, including South San Francisco and Cambridge. Additionally, the company has operations in several European countries, such as Switzerland and the United Kingdom. Prothena's global reach enables it to collaborate with renowned academic institutions, healthcare providers, and research organizations to advance innovative therapies for patients worldwide.

What significant milestones has the company Prothena Corporation achieved?

Prothena Corporation PLC has achieved several significant milestones. The company successfully generated positive results in its Phase 1 clinical trials for PRX002/RG7935, a potential treatment for Parkinson's disease. Furthermore, Prothena entered into a worldwide collaboration with Roche to develop and commercialize PRX002/RG7935, receiving an upfront payment and potential milestone payments. Additionally, Prothena advanced its pipeline with the initiation of Phase 1 clinical trials for PRX004, a potential therapy for ATTR amyloidosis. These milestones demonstrate Prothena Corporation PLC's progress in developing innovative treatments and forging key collaborations in the field of neurodegenerative diseases.

What is the history and background of the company Prothena Corporation?

Prothena Corporation PLC is a biotechnology company specializing in the discovery and development of novel therapies for neurodegenerative diseases. Established in 2012, Prothena originated as a spin-off from Elan Corporation, focusing primarily on antibody-based therapies. The company's research and development efforts are centered around misfolded proteins implicated in diseases like amyloidosis, Parkinson's, and Alzheimer's. With a commitment to scientific innovation, Prothena utilizes its expertise in protein engineering to create transformative treatments. By leveraging its strong pipeline and collaborations, Prothena aims to provide hope to patients suffering from debilitating disorders and improve their quality of life.

Who are the main competitors of Prothena Corporation in the market?

Some of the main competitors of Prothena Corporation PLC in the market include Biogen Inc., Ionis Pharmaceuticals Inc., and Alexion Pharmaceuticals Inc.

In which industries is Prothena Corporation primarily active?

Prothena Corporation PLC is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Prothena Corporation?

The business model of Prothena Corporation PLC revolves around the development and commercialization of novel therapies for the treatment of progressive diseases. Prothena focuses on the discovery and development of protein immunotherapies, specifically targeting misfolded proteins that are implicated in various neurodegenerative diseases. Through its innovative approach, Prothena aims to address unmet medical needs and improve patient outcomes. By leveraging its expertise in protein engineering, it strives to create transformative therapies that have the potential to significantly impact the lives of patients. Prothena Corporation PLC is committed to advancing its pipeline and partnering with strategic collaborators to further accelerate the development and commercialization of its innovative therapies.

What is the P/E ratio of Prothena Corporation 2025?

The Prothena Corporation P/E ratio is -3.35.

What is the P/S ratio of Prothena Corporation 2025?

The Prothena Corporation P/S ratio is 11.61.

What is the Quality Investing of Prothena Corporation?

The Quality Investing for Prothena Corporation is 6/10.

What is the revenue of Prothena Corporation 2025?

The expected Prothena Corporation revenue is 65.21 M USD.

How high is the profit of Prothena Corporation 2025?

The expected Prothena Corporation profit is -225.96 M USD.

What is the business model of Prothena Corporation

Prothena Corporation PLC is a leading biotechnology company specializing in the development of therapies for neurodegenerative diseases. The company, founded in 2012, is headquartered in Dublin, Ireland, and its main focus is on developing drugs against amyloid deposition in brain cells. The company's research and development division is the core of the company, where drugs targeting amyloid deposition in brain cells are developed. Prothena's production department guarantees that the drugs are produced in the highest quality and comply with strict regulatory requirements. Once a drug is approved by the FDA or EMA, Prothena markets and sells it. Prothena has developed NEOD001, a drug in clinical phase III, targeting patients with secondary systemic amyloidosis. The company also has other drugs in the pipeline focusing on Alzheimer's, Parkinson's, and ALS. Overall, Prothena is an innovative biotechnology company that makes a significant contribution to research on neurodegenerative diseases. Its focus on identifying specific antibodies against amyloid deposits in the brain is a promising approach with the potential to improve the lives of millions of people.

What is the Prothena Corporation dividend?

Prothena Corporation pays a dividend of 0 USD distributed over payouts per year.

How often does Prothena Corporation pay dividends?

The dividend cannot currently be calculated for Prothena Corporation or the company does not pay out a dividend.

What is the Prothena Corporation ISIN?

The ISIN of Prothena Corporation is IE00B91XRN20.

What is the Prothena Corporation WKN?

The WKN of Prothena Corporation is A1KAVV.

What is the Prothena Corporation ticker?

The ticker of Prothena Corporation is PRTA.

How much dividend does Prothena Corporation pay?

Over the past 12 months, Prothena Corporation paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Prothena Corporation is expected to pay a dividend of 0 USD.

What is the dividend yield of Prothena Corporation?

The current dividend yield of Prothena Corporation is .

When does Prothena Corporation pay dividends?

Prothena Corporation pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Prothena Corporation?

Prothena Corporation paid dividends every year for the past 0 years.

What is the dividend of Prothena Corporation?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Prothena Corporation located?

Prothena Corporation is assigned to the 'Health' sector.

Wann musste ich die Aktien von Prothena Corporation kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Prothena Corporation from 2/2/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/2/2025.

When did Prothena Corporation pay the last dividend?

The last dividend was paid out on 2/2/2025.

What was the dividend of Prothena Corporation in the year 2024?

In the year 2024, Prothena Corporation distributed 0 USD as dividends.

In which currency does Prothena Corporation pay out the dividend?

The dividends of Prothena Corporation are distributed in USD.

All fundamentals about Prothena Corporation

Our stock analysis for Prothena Corporation Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Prothena Corporation Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.